Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer (Q37427386)

20 August 2017

1 reference

title

Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer (English)

1 reference

20 August 2017

1 reference

Cathy Eng

1

1 reference

PubMed ID

19333227

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Nature Reviews Clinical Oncology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

4

1 reference

20 August 2017

207-218

1 reference

Moving beyond fluorouracil for colorectal cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Cetuximab for the treatment of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Patient-reported outcomes and the evolution of adverse event reporting in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

A review on oxaliplatin-induced peripheral nerve damage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Clinical management of oxaliplatin-associated neurotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

CPT-11-induced cholinergic effects in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Potential regional differences for the tolerability profiles of fluoropyrimidines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Capecitabine as adjuvant treatment for stage III colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Gastrointestinal perforation due to bevacizumab in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Cetuximab therapy and symptomatic hypomagnesemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Chemotherapy in elderly patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Role of panitumumab in the management of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.16

Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.

31 March 2020

1 reference

12 December 2020

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Bevacizumab: serious neurological disorders and nasal perforations

1 reference

12 December 2020

Hypersensitivity Reactions to oxaliplatin: incidence and management.

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

1 reference

12 December 2020

Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective

1 reference

12 December 2020

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

1 reference

12 December 2020

Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.

1 reference

12 December 2020

10.1038/NRCLINONC.2009.16

Identifiers

DOI

1 reference

release_sjg3fuwyijginj3cungryhwzji

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sjg3fuwyijginj3cungryhwzji

24 November 2022

mapped directly with Wikidata item

PubMed ID

19333227

1 reference

PubMed ID

19333227